title: Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
abstract: Metastatic melanoma is a rapidly spreading cancer whose prognosis remains poor although important therapy advances in recent years. Ipilimumab, an anti-CTLA-4 immunotherapy used in advanced melanoma, is an effective immunotherapy alone or combined with other agents but with few predictive biomarkers of response. Here, we sought to analyze the potential of S100B, MIA, soluble MICA, anti-MICA antibodies and LDH as serum biomarkers of response and survival in a cohort of 77 advanced melanoma patients subjected to ipilimumab. Lower levels of S100B, and LDH at baseline and at weeks 3 and 6 correlated to a better response and survival. After multivariate analysis LDH maintained its independence at baseline and week 6, whereas S100B might be a useful tool for anti-CTLA-4 treatment monitoring after the first two doses of ipilimumab (W6). In addition, higher sMICA serum levels at baseline were associated with less frequency of irAEs.
authors.affiliation: INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors.forename: Joana
authors.initials: J
authors.lastname: Felix
authors.affiliation: Laboratoire de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France; Inserm UMRS-1131, Institut Universitaire d'Hématologie, Paris, France.
authors.forename: Bruno
authors.initials: B
authors.lastname: Cassinat
authors.affiliation: Centre d'Epidémiologie Clinique, Hôtel-Dieu, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; INSERM, UMR 1153, Centre de Recherche Epidémiologie et Statistique (CRESS), Paris, France.
authors.forename: Raphael
authors.initials: R
authors.lastname: Porcher
authors.affiliation: Laboratoire de Biologie Cellulaire, AP-HP, Hopital Saint-Louis, Paris, France.
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Schlageter
authors.affiliation: Service de Dermatologie, Hôpital Xavier Bichat, AP-HP, Paris, France.
authors.forename: Eve
authors.initials: E
authors.lastname: Maubec
authors.affiliation: Service de Dermatologie, AP-HP, Hôpital Saint Louis, Paris, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Pages
authors.affiliation: Service de Dermatologie, AP-HP, Hôpital Saint Louis, Paris, France.
authors.forename: Barouyr
authors.initials: B
authors.lastname: Baroudjian
authors.affiliation: Laboratoire d'Immunologie-Histocompatibilité, AP-HP, Hôpital Saint Louis, Paris, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Homyrda
authors.affiliation: INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors.forename: Wahid
authors.initials: W
authors.lastname: Boukouaci
authors.affiliation: INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors.forename: Ryad
authors.initials: R
authors.lastname: Tamouza
authors.affiliation: Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Dermatologie, AP-HP, Hôpital Saint Louis, Paris, France; INSERM UMR-976, Hôpital Saint-Louis, Paris, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Bagot
authors.affiliation: INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Caignard
authors.affiliation: INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
authors.forename: Antoine
authors.initials: A
authors.lastname: Toubert
authors.affiliation: Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Dermatologie, AP-HP, Hôpital Saint Louis, Paris, France; INSERM UMR-976, Hôpital Saint-Louis, Paris, France.
authors.forename: Céleste
authors.initials: C
authors.lastname: Lebbé
authors.affiliation: INSERM UMR-1160, Institut Universitaire d'Hématologie, Paris, France; Université Paris Diderot, Sorbonne Paris Cité, Paris, France. Electronic address: helene.moins@univ-paris-diderot.fr.
authors.forename: Hélène
authors.initials: H
authors.lastname: Moins-Teisserenc
mesh_terms: D000328:Adult; D000368:Aged; D000906:Antibodies / Q000097:blood; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D060908:CTLA-4 Antigen / Q000276:immunology; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D015395:Histocompatibility Antigens Class I / Q000097:blood / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D008545:Melanoma / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods; D009367:Neoplasm Staging; D064568:S100 Calcium Binding Protein beta Subunit / Q000097:blood*; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D016019:Survival Analysis
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D060908:CTLA-4 Antigen; D015395:Histocompatibility Antigens Class I; D000074324:Ipilimumab; C099187:MHC class I-related chain A; D064568:S100 Calcium Binding Protein beta Subunit; C579160:S100B protein, human; D007770:L-Lactate Dehydrogenase
keywords: CTLA-4; Immunotherapy; LDH; Melanoma; S100; sMICA